Bayer completes biggest acquisition in its history

Monsanto business included on prorated basis from June 7 / Group sales advance by 8.5 percent (Fx& portfolio adj.) to 9.481 billion euros / EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effects / Pharmaceuticals registers higher sales (Fx& portfolio adj.) but lower earnings– substantial increase in R&D investment / Consumer Health business weak again / Crop Science achieves strong increase in sales and earnings after weak prior-year quarter / Animal Health improves sales (Fx& portfolio adj.) and earnings / Net income amounts to 799 million euros / Core earnings per share up by 1.3 percent at 1.54 euros / Group outlook for 2018 confirmed, with adjustments to reflect acquisition
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news